Lionco Pharm Grp Co Ltd Market Cap ($558.71 Million)
Market Cap & Net Worth: Lionco Pharm Grp Co Ltd (603669)
Lionco Pharm Grp Co Ltd market cap. Lionco Pharm Grp Co Ltd (SHG:603669) has a market capitalization of $558.71 Million (CN¥3.82 Billion) as of November 1, 2026. Listed on the SHG stock exchange, this China-based company holds position #11288 globally and #3070 in its home market, demonstrating a -16.64% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Lionco Pharm Grp Co Ltd's stock price CN¥5.36 by its total outstanding shares 712331165 (712.33 Million). Also see Lionco Pharm Grp Co Ltd operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Lionco Pharm Grp Co Ltd Market Cap History (2015–2026)
Lionco Pharm Grp Co Ltd market cap history from 2015 to 2026. Data shows change from $1.09 Billion to $558.71 Million (-4.52% CAGR). Check latest Lionco Pharm Grp Co Ltd stock price today for real-time trading data and today's change.
Lionco Pharm Grp Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Lionco Pharm Grp Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Lionco Pharm Grp Co Ltd (603669) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.47x
Lionco Pharm Grp Co Ltd's market cap is 1.47 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $954.97 Million | $478.59 Million | $153.93 Million | 2.00x | 6.20x |
| 2017 | $632.84 Million | $1.01 Billion | $161.01 Million | 0.63x | 3.93x |
| 2018 | $455.14 Million | $1.67 Billion | $182.70 Million | 0.27x | 2.49x |
| 2019 | $512.36 Million | $1.64 Billion | $201.59 Million | 0.31x | 2.54x |
| 2020 | $865.30 Million | $1.00 Billion | $160.07 Million | 0.86x | 5.41x |
| 2021 | $1.03 Billion | $740.33 Million | $65.90 Million | 1.39x | 15.56x |
| 2022 | $598.32 Million | $289.26 Million | -$195.86 Million | 2.07x | N/A |
| 2023 | $576.43 Million | $196.83 Million | -$151.50 Million | 2.93x | N/A |
| 2024 | $547.24 Million | $379.78 Million | -$130.76 Million | 1.44x | N/A |
| 2025 | $475.32 Million | $322.48 Million | -$193.24 Million | 1.47x | N/A |
Competitor Companies of 603669 by Market Capitalization
Companies near Lionco Pharm Grp Co Ltd in the global market cap rankings as of November 1, 2026. Also see 603669 asset base for a full breakdown of the balance sheet.
Key companies related to Lionco Pharm Grp Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #535 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #593 globally with a market cap of $45.23 Billion USD ( CN¥309.13 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #535 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.62 |
| #593 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.23 Billion | CN¥48.46 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.30 |
Market Capitalization of Lionco Pharm Grp Co Ltd (2015–2026)
Market capitalization of Lionco Pharm Grp Co Ltd from 2015 to today. Between 2015 and today, Lionco Pharm Grp Co Ltd's market cap moved from $1.09 Billion to $ 558.71 Million, with a yearly change of -4.52%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥558.71 Million | +17.54% |
| 2025 | CN¥475.32 Million | -13.14% |
| 2024 | CN¥547.24 Million | -5.06% |
| 2023 | CN¥576.43 Million | -3.66% |
| 2022 | CN¥598.32 Million | -41.66% |
| 2021 | CN¥1.03 Billion | +18.53% |
| 2020 | CN¥865.30 Million | +68.88% |
| 2019 | CN¥512.36 Million | +12.57% |
| 2018 | CN¥455.14 Million | -28.08% |
| 2017 | CN¥632.84 Million | -33.73% |
| 2016 | CN¥954.97 Million | -12.70% |
| 2015 | CN¥1.09 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Lionco Pharm Grp Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $558.71 Million USD |
| MoneyControl | $558.71 Million USD |
| MarketWatch | $558.71 Million USD |
| marketcap.company | $558.71 Million USD |
| Reuters | $558.71 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Lionco Pharm Grp Co Ltd
Lionco Pharmaceutical Group Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products and medical services in China. It offers chemical and prescription drugs for nutrition, antimicrobial, antiviral, digestive, cardiovascular, cerebrovascular, detoxification, anti-tumor, anti-infective drugs, and other applications. Lionco Phar… Read more